27.02.2024 | Research Letter
Outcomes of patients with hypertrophic cardiomyopathy undergoing percutaneous left atrial appendage occlusion
verfasst von:
Siddharth Agarwal, Muhammad Bilal Munir, Christopher V. DeSimone, Abhishek Deshmukh, Mohamad Adnan Alkhouli, Zain Ul Abideen Asad
Erschienen in:
Journal of Interventional Cardiac Electrophysiology
|
Ausgabe 4/2024
Einloggen, um Zugang zu erhalten
Excerpt
Hypertrophic cardiomyopathy (HCM) is the most common inherited cardiomyopathy and approximately 20-30% of these patients develop atrial fibrillation (AF) [
1]. These patients have a high risk of thromboembolism and the predictive capability of the CHA
2DS
2-VASc score is limited in this cohort. Therefore, guidelines strongly recommend empiric long-term anticoagulation for all patients [
2]. In patients with HCM and AF that are unable to safely tolerate long-term anticoagulation, percutaneous left atrial appendage occlusion (LAAO) may have an important role in mitigating the risk of stroke risk [
2]. However, there is limited data on the safety and efficacy of LAAO device implantation in patients with HCM. Therefore, we examined the outcomes of patients with HCM undergoing LAAO device implantation in a nationally representative cohort of patients. …